Stock Ticker

  • Loading stock data...

High Flyers: CalAmp Corp. (NASDAQ:CAMP), Energy Focus Inc (NASDAQ:EFOI), Chimerix Inc (NASDAQ:CMRX)

Boston, MA 10/08/2014 (wallstreetpr) – Stock of CalAmp Corp. (NASDAQ:CAMP) was in big demand at the markets on 7th October, a day after it announced its 2Q FY 2015 operations report. Following the impressive results, analyst Rajesh Ghai of Macquarie Research went on to upgrade the stock to Outperform. The price target has been retained at previous $23 by Macquarie Research. The research firm has opined that the firm is on the verge of achieving a substantial and sustained increase in its “revenue and earnings” over the next few quarters. “Wireless Datacom segment” has been identified as a specific area of strength for CalAmp Corp. (NASDAQ:CAMP) by the research firm. Shares of CalAmp Corp. (NASDAQ:CAMP) moved up sharply by 21.03% to close at $19.97.

The stock of energy-efficient light emitting diode manufacturer Energy Focus Inc (NASDAQ:EFOI) surged upwards during 7th October trading by 16.92% to close at $6.91. After it announced that it has been awarded another substantial work order worth $7.9 million by the United States Navy. In mid September, United States Navy had awarded the LED manufacturer a $7.7 million contract. The latest order fulfilment is expected to be completed by June 2015, the firms press note indicated. The products to be supplied are “military Intellitube(R) LED retrofit tubes.” The press note also indicated that these installations are extremely popular lighting solutions for the Navy. It has been installed in more than 160 naval vessels, the firm has indicated.

Investors trooped into the stock of Biopharmaceutical company Chimerix Inc (NASDAQ:CMRX) on 7th October after the Nebraska Medical Centre announced that one of the suspect Ebola patient is being treated with a test drug brincidofovir developed by Chimerix Inc (NASDAQ:CMRX). The treatment is being administered at the Biocontainment Unit of Nebraska Medical Center. The care givers have come to the conclusion after examining the recovery of the patient and the supporting data, that “brincidofovir” is the best bet for them right now to treat Ebola. On 6th October, U.S Food and Drug Administration had approved the use of brincidofovir to treat Ebola patients on an experimental basis. Shares closed up by 5.59% at $33.23.

Published by Pushpa Naresh

Pushpa Naresh has done MBA (Finance) and an avid market tracker. She is a technical analyst who closely tracks US markets along with other global markets like India. She has been expressing her views about markets and also advises various clients.

Recent Stories

SignUp Now For Our Featured Newsletter